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ABSTRACT
Background: Despite a reduction in the incidence of cytomegalovirus (CMV) infections after kidney 
transplantation, less is known about late CMV infection in kidney transplant recipients.
Objective: To assess incidence of CMV infection in a cohort of patients under a high surveillance CMV 
prevention protocol and identify factors associated with late CMV infection. 
Methods: Analysis of a consecutive cohort of 181 kidney allograft recipients between January 2012 
and Aug 2015. CMV prevention-protocol consisted of 6-month universal prophylaxis and pre-emptive 
therapy for high-risk group (D+/R– or patients submitted to lymphocyte-depleting agent for induction or 
rejection treatment) and pre-emptive therapy for standard-risk group (D±/R+). Stopping valganciclovir 
was followed by CMV screening in the next two appointments.
Results: CMV infection was identified in 73 of 181 patients; the rate in high-risk group and standard-risk 
group was similar (p=0.443). However, in the latter group, the infection occurred mostly in the first 6 
months. Late CMV infection occurred in 25 of 181 patients (5 of standard-risk group and 20 of high-risk 
group), after a median (IQR) of 253 (230.3–312.3) days after transplantation and 55 (41–89.5) days after 
the protocol period. Screening for CMV after valganciclovir discontinuation revealed 56% of late CMV 
infections. In high-risk group, D+/R– was associated with late CMV infection (HR 2.7, p=0.039) and in 
standard-risk group; lower age was associated with late CMV infection (HR 0.89, p=0.02).
Conclusion: The incidence of CMV infection was similar to that reported in the literature. In high-risk 
patients, antigenemia surveillance during prophylaxis did not appear to reduce late CMV infections. 
Antigenemia screening after valganciclovir had limited results in the diagnosis of late CMV infection. 
D+/R– was associated to late CMV infection in high-risk group. Lower age appeared to influence late CMV 
infection in standard-risk group. 
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INTRODUCTION
Cytomegalovirus (CMV) infection is a common complication after renal transplantation [1]. In addition to di-
rect effects of CMV, its indirect effects that 
further contribute to the morbidity associated 
with CMV infection have been identified [2]. 
Patients with CMV infection are at increased 
risk of renal graft loss, cardiovascular events 
and mortality [3, 4]. Prevention of CMV in-
fection with pharmacological prophylaxis or 
pre-emptive treatment led to considerable re-
duction in the incidence of the infection and its 
seriousness [1, 5-7]. The recommendations of 
the Spanish Societies of Transplantation and 
Infectious Diseases [7] propose universal pro-
phylaxis for 3–6 months in high-risk patients 
(recipients with prior negative IgG serology 
for CMV who received grafts from positive 
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donors [D+/R–] or induction therapy with 
lymphocyte-depleting agents), followed by an 
undefined screening period [7]. This recom-
mendation highlights the risk of late-onset 
CMV disease, occurring in up to 37% of D+/
R– kidney transplant recipients after the end 
of six months prophylaxis [8]. Screening for 
the viral load eight weeks after stopping pro-
phylaxis was found to be of limited benefit be-
cause a great proportion of late onset disease 
in solid organ transplants was diagnosed after 
that period [9]. Therefore, it is important to 
identify patients at greater risk of developing 
late CMV infection, since CMV D+/R– is the 
only well-established risk factor [10]. 
A cohort of patients received a CMV prevention 
protocol that used universal prophylaxis and 
pre-emptive therapy in high-risk patients and 
pre-emptive therapy for the standard-risk 
patients, followed by a screening period after 
valganciclovir therapy. The objective of this 
study was to assess the effect of using this 
prevention protocol on the incidence of CMV 
infection, including late CMV infection (after 
the prevention protocol period) and identify 
factors associated with late CMV infection. 
MATERIAL AND METHODS
Study Population
We analyzed all consecutive adult allograft 
recipients followed (or transplanted) in our 
unit between January 2012 and August 2015. 
The exclusion criteria were follow-up less 
than six months (n=14) and recipients with 
prior negative serology for CMV who received 
grafts from negative donors (n=4). We 
included 181 patients who underwent the same 
maintenance immunosuppressive protocol and 
CMV preventive protocol.
The standard immunosuppression was 
a triple-drug regimen with tacrolimus, 
mycophenolate mofetil and steroids. 
According to immunological risk, patients 
received induction therapy with basiliximab 
(n=99) and antithymocyte globulin (ATG) 
or thymoglobulin (TG) (n=82). A subgroup 
of patients was also treated with intravenous 
immunoglobulin and rituximab (n=16). 
Recent rejection treatment was defined as 
additional immunosuppressive therapy given 
three months prior to the diagnosis of CMV 
infection. 
All patients were followed in our unit and 
laboratory tests were performed weekly in 
the first month, 1–3-week intervals until six 
months, 2–6-week intervals until 12 months, 
and every two months during the second year.
CMV Infection Prevention Protocol
Patients were divided into two groups 
based on CMV infection risk—high-risk 
group comprising of D+/R–, patients who 
received lymphocyte-depleting agents as 
induction therapy or for acute rejection 
episode. This group received universal 
prophylaxis with oral valganciclovir (900 
mg/day and adjusted for CrCl < 60 min/
min) for six months. In the same period, all 
patients were screened for CMV antigenemia 
(CMVpp65 antigenemia test) at every clinic 
visit and on the two subsequent visits after 
valganciclovir discontinuation. Those with 
clinically significant CMV antigenemia were 
treated. Prophylaxis and screening were also 
maintained up to six months after rejection 
treatment. The standard-risk group included 
recipients with prior positive IgG serology 
for CMV who received grafts from positive 
or negative donors (D±/R+); no lymphocyte-
depleting agent was used as induction therapy 
or anti-rejection treatment. This group was 
submitted to pre-emptive therapy. CMV 
antigenemia was screened for six months in 
every clinical visit; valganciclovir was started 
if clinically significant CMV antigenemia 
occurred.
In both groups, clinically significant CMV 
antigenemia were treated based on physician’s 
opinion who considered patient’s risk factors 
(cumulative immunosuppression, recipient 
CMV IgG negative) and presence of CMV 
infection-related symptoms. In the remaining 
cases, immunosuppression was reduced 
whenever possible.
The treatment consisted of valganciclovir 
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(900 mg bid, adjusted for CrCl < 60 min/
min) until a negative CMV antigenemia result 
was attained followed by a variable sustained 
treatment period. All patients were screened 
for CMV antigenemia in two subsequent visits 
after discontinuation of the treatment.
CMV Infection Definition
CMV infection was defined as evidence of 
CMV replication regardless of symptoms [7, 
11], i.e., at least one positive CMV antigenemia 
with one or more positive cells per 2×105 
cells examined. Positive antigenemia were 
treated according to the caring physician’s 
opinion. Severe CMV disease was considered 
in patients with CMV infection accompanied 
by clinical signs and symptoms that required 
hospitalization.
Early CMV infection was defined as all the 
positive CMV antigenemia occurring during 
the protocol period (up to six months). Late 
CMV infection was defined as all the positive 
CMV antigenemia after the protocol period 
(after six months). These infections were 
classified as reactivations or primary late 
infections. 
Statistical Analysis 
The data collected from patients’ medical charts 
were reviewed. The baseline data included 
age, sex, race, primary renal disease, diabetes 
mellitus, renal replacement therapy prior 
to transplantation, length of pretransplant 
dialysis, donor source, CMV status prior to 
transplantation (CMV IgG donor/recipient), 
cold ischemia time, HLA mismatch, and 
induction therapy. Follow-up data included 
CMV infection, severe CMV disease, early 
CMV infection, late CMV infection, time 
until CMV infection, time until late CMV 
infection, time until late CMV infection after 
the protocol, rejection treatment (and recent 
rejection treatment), estimated glomerular 
filtration rate (eGFR) using the Chronic 
Kidney Disease Epidemiology Collaboration 
formula at the 1st, 6th, 12th, and 24th months, 
mortality, and graft loss.
Data were expressed as number (%) or median 
(IQR). Statistical significances between the 
groups were measured by Mann-Whitney U 
test for continuous variables without normal 
distribution, and by χ2 or Fisher exact test for 
categorical variables. Cox regression analysis 
was used to identify independent factors asso-
ciated with late CMV antigenemia using time 
to late CMV antigenemia after the protocol. 
Variables with p value <0.1 in univariate anal-
ysis were included in the multivariate model. 
Age, sex and CMV-prevention protocol group 
were forced into the multivariate model. Cold 
ischemic time was defined as being 20 min 
for living-donor recipients for Cox regression 
analysis. SPSS® for Windows® ver 17.0 (SPSS 
Inc, Chicago, IL, USA) was used for data anal-
ysis. A p value <0.05 was considered statisti-
cally significant.
RESULTS
We studied 181 kidney (110 male, 60.8%) 
recipients with a median (IQR) age of 54 
(41.5–61) years (Table 1). During a median 
(IQR) follow-up of 29.3 (17–40.3) months, 
three patients died from sepsis, H1N1 infection, 
and unknown cause; and five lost their grafts. 
Reasons for graft loss were acute rejection, 
chronic rejection, two relapses of primary 
renal disease, and urologic complication. 
Deaths or graft losses were not associated 
with valganciclovir or CMV infection. Acute 
rejection was diagnosed in 18 (9.9%) patients.
During the follow-up, 73 (40.3%) patients had 
positive CMV antigenemia after a median 
(IQR) of 60 (39.5–154.5) days of transplantation 
(Fig 1). In CMV-positive patients, the median 
(IQR) maximal antigenemia was 7 (3–35.5) 
cells/2×105. Fifty-nine (32.6%) patients were 
treated (Table 2). The median (IQR) maximal 
antigenemia in treated patients was 15.5 (5–
65) cells/2×105. Five (2.8%) had severe CMV 
infection—3 happened after the protocol 
period. There were no significant difference 
between patients who developed CMV 
infection compared with those who did not 
in terms of graft loss (p=0.43) and mortality 
(p=0.59).
Considering CMV-prevention protocol, 98 
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Table 1: Characteristics of patients with late CMV infection vs. no late CMV infection. Values are either median 
(IQR) or n (%).
Parameters Total (n=181) No late CMV infec-tion (n=156)




Age 54 (41.5–61) 56 (43.3–62) 45 (33–52.5) 0.001
Male 110 (60.8) 96 (61.5) 14 (56) 0.599
Caucasian 148 (81.8) 129 (82.7) 19 (76) 0.411
Diabetes 20 (11.0) 20 (12.8) 0 (0) 0.081
Primary renal disease
DM 15 (8.3) 14 (9.0) 1 (4)
0.536
GN 33 (18.2) 27 (17.3) 6 (24)
ADPKD 22 (12.2) 20 (12.8) 2 (8)
Others 63 (34.8) 51 (32.7) 12 (48)
Unknown 48 (26.5) 44 (28.2) 4 (16)
HD/PD 143 (79.0)/29 (16.0) 126 (80,8)/17 (9.2) 17 (80)/5 (20)
0.137





71.3 (42.3–95.6)  
n=148
57.6 (31.2–92)  
n=22 0.263
CMV status prior to KT
D–/R+ 15 (8.3) 14 (9) 1 (4)
0.013D+/R+ 143 (79.0) 127 (81.4) 16 (64)
D+/R– 23 (12.7) 15 (9.6) 8 (32)
CMV-prevention protocol
Standard risk group 83 (45.9) 78 (50) 5 (20)
0.005
High risk group 98 (54.1) 78 (50) 20 (80)
Deceased donor 155 (85.6) 136 (87.2) 19 (76)
0.214
Living donor 26 (14.4) 20 (13.8) 6 (24)
HLA-A.B. DR mismatch 4 (3–4) n=180 4 (3–5) n=155 4 (3–4) 0.825





Induction therapy on KT
Basiliximab 99 (54.7) 87 (55.8) 12 (48)
0.358
ATG/TG 82 (45.3) 65 (44.2) 13 (52)
Rejection treatment at 6 
months 10 (5.5) 8 (5.1) 2 (8) 0.631
Recent rejection treatment 5 (2.8) 4 (2.6) 1 (4) 0.529
eGFR after
1 month 54 (40–67) 53 (43–71.8) 58 (40.7-69.3) 0.912
6 months 57 (46–70.5) 55.5 (46–68.8) 64.5 (50.5–73.5) 0.503
12 months 57 (46–70) n=159 56.6 (46–69.8) 60 (50.8–77.8) 0.333
24 months 60 (46–71.8) n=112 60 (46–72.8) 60 (43.75–66.5) 0.848
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(54.1%) patients were included in high-risk 
group and 83 (45.9%) in the standard risk-
group (Table 2). In standard-risk group, the 
majority of CMV infection occurred during 
the protocol period; in high-risk group, ap-
proximately half of the incidents occurred 
during the protocol period and the other half 
happened thereafter (Table 2). There were no 
differences between the two groups in terms 
of the number of CMV infected patients 
(p=0.443) or treated patients (0.897) during 
the follow-up. Nor was a significant (p=0.358) 
difference in the incidence of severe CMV in-
fections between the high-risk and standard-
risk group.
Late CMV infection occurred in 13.8% of 
patients (n=25, 5 in the standard-risk group 
and 20 in high-risk group) (Table 2). In the 
standard-risk group, the majority of late CMV 
infections corresponded to reactivation of the 
virus; in the high-risk group it attributed to 
primary infections. In the high-risk group, 
lymphocyte-depleting treated patients had 
lower incidence of late CMV infection com-
pared with D+/R– patients (16% vs. 34.7%, 
respectively) (Table 2). Late CMV infection 
patients were younger and more likely D+/R– 
(Table 1). 
The median (IQR) time to late CMV infec-
tion was 253 (230.3–312.3) days after trans-
plantation, corresponding to a median (IQR) 
of 55 (41–89.5) days after the protocol period. 
Screening for CMV antigenemia in the next 
two appointments after stopping valganciclo-
vir treatment or prophylaxis period only al-
lowed for the diagnosis of 56% of late infec-
tions. A screening period of 100 days after 
valganciclovir could have allowed for the diag-
nosis of 83.3% of late CMV infections. In the 
high-risk group, the screening after prophy-
laxis identified 12 (60%) of 20 positive patients; 
in the standard-risk group the screening after 
Continued
Table 1: Characteristics of patients with late CMV infection vs. no late CMV infection. Values are either median 
(IQR) or n (%).
Parameters Total(n=181)
No late CMV infec-
tion
(n=156)




Protocol period (days)† 190 (159.5–220.5) 194 (161.5–200.5) 189.5 (159.3–222.8) 0.897
Follow-up (months) 29.3 (17–40.3) 29.7 (16.7–40.9) 26.6 (19.4–37.3) 0.844
*Living donors were not included; †Includes prophylactic and screening period. CMV:  cytomegalovirus; DM: diabetes mellitus; GN: glomer-
ulonephritis; ADPKD: autosomal dominant polycystic kidney disease; HD: hemodialysis; PD: peritoneal dialysis; KT: kidney transplantation; 
D+/R–: CMV IgG donor positive, recipient negative; D+/R+: CMV IgG donor positive, recipient positive; D–/R+: CMV IgG donor negative, 
recipient positive; ATG/TG: antithymocyte globulin/thymoglobulin; eGFR: estimated glomerular filtration rate 
Figure 1: CMV infection classification
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treatment identified 2 of 4 reactivations.
Cox regression analysis showed a tendency to 
high-risk group and D+/R– patients to expe-
rience late CMV infection (Table 3). The same 
model was applied separately to the high-risk 
and standard-risk groups. In the high-risk 
group, D+/R– was associated with late CMV 
infection (HR 2.7, p=0.039). Cold ischemic 
time had a HR close to 1 (HR 0.999, p=0.013). 
In the standard-risk group the multivariable 
analysis was performed using CMV donor sta-
tus (D+ vs. D–) instead of CMV recipient sta-
tus since all recipients were CMV IgG posi-
tive. The analysis showed that although with 
small effect, age was associated with CMV 
infection (HR 0.89, p=0.02). The identified 
factors were then analyzed with Kaplan-Meier 
survival analysis. In the high-risk group, us-
ing time to late CMV infection after cessation 
of the protocol, D+/R– status showed a higher 
cumulative probability of CMV late infection 
(Figure 2A). In the standard-risk group, those 
aged ≤40 years had a higher probability of 
CMV infection (Figure 2B).
DISCUSSION
In this cohort of adult kidney transplant re-
cipients receiving a high surveillance protocol, 
the incidence of CMV (and late CMV) infec-
tion was similar to what has been reported 
in previous studies. To better understand 
the clinical course of late CMV infection, we 
analyzed its potential risk factors. We found 
that in the high-risk group, D+/R– was an 
important risk factor and, with a small effect, 
in the standard-risk group, lower age was as-
sociated with late CMV infection. As part of a 
high surveillance protocol, screening of CMV 
antigenemia after stopping valganciclovir did 
not appear to be useful in the diagnosis of late 
CMV infection. 
We observed a rate of 37.8% positive CMV 
antigenemia in the high-risk group; the rate 
was 43.5% in the standard-risk group. In a 
previous study using similar protocol but with 
a three-month protocol period, the incidence 
of CMV viremia was higher in the high-risk 
group (47% positive CMV PCR) and lower in 
the standard-risk group (30%) [12]. Our six-
month protocol-period might contributed to 
the lower incidence of the infection observed 
in the high-risk group, probably because a 
six-month prophylaxis would be related to 
lower incidence of CMV infection compared 
with that a three-month period would [13]. 
Regarding the standard-risk group, we used 
anti-IL2 in the induction therapy, which could 
contribute to the higher incidence of CMV 
Figure 2: Cumulative probability of developing late CMV infection. A) The high-risk group according to CMV 
status (R+ vs. R–), Log Rank p=0.035; R+: 74 patients at risk with 12 events; R–: 23 patients at risk with 8 
events. B) The standard-risk group according to age group (≤40 years vs. >40 years), Log Rank p=0.042. ≤40 
years: 18 patients at risk with 3 events; >40 years: 65 patients at risk with 2 events. 
CMV: cytomegalovirus; R+: CMV IgG recipient positive; R–: CMV IgG recipient negative 
Late CMV Infection in Kidney Tx Recipients
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infection observed in the current study. In a 
large retrospective study with R+ patients, 
the use of pre-emptive strategy in the first 
six months was associated with a 48% as-
ymptomatic CMV infection rate; the rate was 
49% after 12 months, which is similar to our 
results [25]. Regarding the high-risk group, 
another study found 29% positive CMV vire-
mia (≥2000 copies/mL) within 100 days pro-
phylaxis therapy in a group of patients treated 
with thymoglobulin [14]. The higher rate of 
CMV positive patients in our series could be 
related to the lower cut-off value we used. Li, 
et al, reported that a cut-off of 1000 CMV cop-
ies/mL corresponds to antigenemia levels of 
one positive cell per 2×105 [15]. In fact, a cut-
off point of 900 copies/mL had 100% sensitiv-
ity and 82.5% specificity for the diagnosis of 
active and symptomatic CMV infections [22].
As described in the literature [12, 14], most of 
the CMV infections observed in the standard-
group occurred during the protocol period. On 
the other hand, in the high-risk group, these 
infections occurred with almost the same inci-
dence during and after the protocol period, in 
line with the observation that universal pro-
phylaxis could delay the appearance of CMV 
infection [13, 14, 16]. Although these two 
groups had different risk factors for CMV in-
Table 3: Univariate and Cox regression analyses of factors affecting late CMV infection. Multivariate model χ2= 
24.3, p<0.001.
Factors for late CMV infection
Univariate model* Multivariate model†
HR (95% CI) p value HR (95% CI) p value
Age 0.95 (0.92–0.98) 0.002 0.98 (0.94–1.02) 0.287
Male sex 0.81 (0.36–1.79) 0.609 0.98 (0.409–2.35) 0.963
Diabetes 0.04 (0–8.33) 0.239
CMV status prior to KT
D±/R+ 1 — 1 —
D+/R– 3.82 (1.65–8.87) 0.002 2.29 (0.89–5.92) 0.086
CMV-prevention protocol
Standard risk 1 — 1 —
High risk 3.62 (1.35–9.64) 0.010 2.04 (0.98–9.43) 0.054
Second transplant 0.99 (0.23–4.21) 0.993
Living donor 1 —
Deceased donor 0.49 (0.19–1.22) 0.126
HLA-A.B. DR mismatch 0.98 (0.73–1.32) 0.915
Cold ischemic time (min) 0.999 (0.998–1) 0.034 0.999 (0.998–1) 0.069
Induction therapy on KT 
Basiliximab 1 —
ATG/TG 1.3 (0.6–2.87) 0.503
Rejection treatment at 6 months 0.99 (0.98–1.0) 0.178
Recent rejection treatment 0.71 (0.17–3.0) 0.641
Protocol Period (days)† 1 (0.99–1.01) 0.623
Factors included in multivariate model were those reported in multivariate column. *Recent rejection treatment as a time-dependent variable 
(Cox proportional hazards model); †Includes prophylaxis, treatment and pre-emptive period before late CMV infection. CMV: cytomegalo-
virus; KT: kidney transplantation; D+/R–: CMV IgG donor positive, recipient negative; D±/R+: CMV IgG donor positive/negative, recipient 
positive; ATG/TG: antithymocyte globulin/thymoglobulin
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fection, when patients randomized into either 
prophylaxis or pre-emptive therapy without 
significant differences in terms of their CMV 
serostatus or immunosuppression, late CMV 
viremia occurred more frequently in prophy-
laxis group [14].
We had 25 late CMV infections, mostly in the 
high-risk group and rarely in the standard-risk 
group. The incidence of late CMV infection in 
D+/R– patients reported previously is vari-
able [8, 13, 17, 18]. In a randomized controlled 
trial, the incidence of CMV disease (CMV syn-
drome or tissue invasive disease) in D+/R– pa-
tients during a 200-day period of prophylaxis 
was 7.1%; one year post-transplantation, it was 
16.1% [13]. The same cohort was followed for 
two years and the incidence of CMV disease 
came up to 21.3% [17]. However, the incidence 
of CMV viremia (viral load >600 copies/mL) 
was 18.7% at six months and 37.4% one year 
post-transplantation [13]. Jamal, et al, also re-
ported a 30% cumulative incidence of CMV in-
fection in D+/R– patients after one year after 
cessation of a 3–6 month prophylaxis course 
[10]. Other authors reported an incidence of 
37% primary late-onset CMV infection (posi-
tive viremia with symptoms) in D+/R– pa-
tients after six months of valganciclovir pro-
phylaxis [8]. We reported 34.7% incidence of 
positive CMV antigenemia in D+/R– patients 
that could overestimate the CMV infection 
rates reported in previous studies. Regarding 
to patients treated with lymphocyte-depleting 
agents, we only identified one small study re-
porting the frequency of late CMV viremia 
in patients receiving a 100-day prophylaxis 
course in which 98% were treated with lym-
phocyte-depleting agents. The frequency of 
late CMV viremia was 22% (11 of 49 patients). 
The higher incidence observed could be at-
tributed to the shorter prophylaxis period and 
different screening methods used. However, 
most studies [8, 10, 13, 17-19] did not consider 
screening during the period of prophylaxis 
and only screened patients with symptoms. In 
our study, the high-risk group was submitted 
to a more aggressive surveillance, including 
valganciclovir prophylaxis and screening for 
CMV antigenemia during the protocol peri-
od. This allowed switching for valganciclovir 
therapeutic dose in antigenemia positive cases. 
However, this measure did not seem to have 
contributed to a lower incidence of late CMV 
disease because those continued to be primary 
CMV infections. This result suggested that 
late CMV infection in high-risk patients did 
not appear to be related to undiagnosed low-
grade CMV infection during the protocol pe-
riod since its identification by antigenemia and 
treatment did not seem to reduce the incidence 
of the infection. On the other hand, positive 
viral load seemed to have a prognostic value. 
In a recent study, CMV testing was performed 
monthly throughout the first year post-trans-
plantation. R+ patients received valganciclovir 
prophylaxis for 100 days; D+/R– received the 
prophylaxis for 200 days. In 30.6% of patients, 
the viral load was detectable at least once dur-
ing the follow-up; a viral load >656 copies/
mL was significantly associated with higher 
mortality [23]. In another study, asymptom-
atic CMV viremia was associated with chronic 
graft disfunction [24]. 
The low incidence of late CMV infection 
observed in the standard-risk group is also 
reported in two others studies. In one, the 
authors did not observe primary late-onset 
CMV viremia after 100 days of pre-emptive 
therapy, but recurrence occurred in 4% (1 of 13 
patients) of D+/R+ but in none of nine D-/R+ 
patients [14]. In another study, asymptomatic 
CMV infection rate was 48% after six months; 
it only increased to 49% after 12 months [25].
Screening after prophylaxis period has been 
recommended. But only few reports address 
this issue [7]. Many of those were done after 
100 days of prophylaxis in high-risk patients 
(D+/R–) and only one reported results in lower-
risk patients (R+) [2]. Blanco, et al, concluded 
that the performance of a CMV viremia 
monitoring every 15 days during and after 
three months of valganciclovir prophylaxis 
did not appear to be useful in R+ patients with 
less conclusive data on D+/R– patients [20]. 
The authors described that 18 (32%) of 56 R+ 
patients had positive CMV viremia (all bellow 
the established cut-off value of 10,000 copies/
mL) and only two developed CMV disease. 
In D+/R– patients 13 (43%) of 30 had CMV 
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viremia, of whom seven developed late-onset 
CMV disease [20]. Our screening also had 
limited results, as just allowed for the diagnosis 
of 56% of those with late CMV antigenemia. 
Regarding D+/R– solid organ transplant 
recipients, Lisboa, et al, showed that 8-weekly 
screening for CMV viremia after 3–6 months 
of valganciclovir prophylaxis, did not appear 
to be of value because of rapid viral doubling 
time, and that 55.2% of CMV disease occurred 
after the surveillance period [9]. We observed 
similar results probably because our median 
time to late CMV infection after the protocol 
was similar to their screening period (55 days 
≈ 8 weeks). In a cohort of D+/R– kidney 
transplant, the median time to late CMV 
infection after six months of prophylaxis was 
also similar—67 days [8]. A longer screening 
period could increase the ability to identify 
positive CMV antigenemia patients. However, 
the specificity of those results, the frequency 
of screening and the cost-effectiveness of that 
measure need to be addressed in future studies.
When considering all patients, D+/R– was 
almost significantly associated with CMV 
infection in multivariate analysis. D+/R– has 
been identified as a risk factor for late CMV 
disease in a cohort of kidney transplant recipi-
ents (D+/R– and R+) receiving the same pro-
tocol (a 3–6-month prophylaxis course) [10]. 
In our study the patients received different 
protocols according to their CMV infection 
risks. In the high-risk group, D+/R– was as-
sociated with late CMV antigenemia indepen-
dently of induction therapy and prophylaxis 
duration. This result was expected since the 
incidence of late CMV antigenemia was higher 
in D+/R– compared with that in R+ patients 
treated with lymphocyte-depleting agent. 
Furthermore, our high surveillance protocol, 
D+/R– continued to be an important factor to 
be considered; a previous report did not find 
other risk factors for late CMV infection in 
this group of patients [8]. In the standard-
risk group, age appeared to be an independent 
risk factor associated with late CMV infection. 
However, this group only had five cases of late 
CMV infection and thus recommendations on 
higher surveillance on younger patients is lim-
ited and further studies are needed. Estimated 
GFR <45 mL/min at prophylaxis cessation 
and delayed graft-function have been identi-
fied as risk factors for late CMV infection [10, 
21].
This study had few limitations to address. As 
this was a retrospective analysis, it was not 
possible to identify all patients with CMV 
disease from patients’ records. Because the 
cut-off values used to start treatment after a 
positive CMV antigenemia varied according 
to the caring physician, we used a broader 
definition of CMV infection, including all 
patients with positive CMV antigenemia. This 
might overestimated our results. The screening 
surveillance of CMV replication was done 
using CMV pp65 antigenemia, which is a semi-
quantitative test with limitations. Samples 
need to be processed within 6–8 hours and 
assay performance diminishes with less than 
1000 neutrophils/μL. The recommendations 
of the Spanish Societies of Transplantation and 
Infectious Diseases propose real-time QNAT 
methods for monitoring CMV infection [7]. 
Additionally, we did not have a control group 
without screening during administration 
of the prophylaxis to compare the effect of 
this measure on the incidence of late CMV 
infection. The screening after prophylaxis/
treatment had an important limitation since 
it was done in an irregular period. Finally, 
our sample only developed 25 late CMV 
infections that could limit the study power of 
our research. 
In conclusion, we found that the incidence 
of CMV infection in our cohort was similar 
to what had been reported in the literature. 
Antigenemia surveillance during prophylaxis 
in high-risk patients did not appear to reduce 
the incidence of late CMV infections when 
comparing to literature reports. Screening in 
the two visits after prophylaxis or treatment 
turned out to be of limited value in the 
diagnosis of late CMV infections. D+/R– 
serostatus was identified as a risk factor for 
late CMV infection in our high-risk group. 
Lower age appeared to be related to late CMV 
infection in standard-risk patients. 
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